(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: Cholecystokinin (CCK) is a gastrointestinal hormone that has been proposed as a potential therapeutic option for obesity-diabetes. As such, (pGlu-Gln)-CCK-8 is an N-terminally modified CCK-8 analogue with improved biological effectiveness over the native peptide.METHODS: The current study has examined the in vitro stability, biological activity and in vivo therapeutic applicability of a novel second generation mini-PEGylated form of (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG].RESULTS: (pGlu-Gln)-CCK-8[mPEG] was completely resistant to enzymatic degradation and in addition displayed similar insulinotropic (p
LanguageEnglish
Pages4009-4016
JournalBBA - General Subjects
Volume1830
Issue number8
DOIs
Publication statusPublished - 10 Apr 2013

Fingerprint

Cholecystokinin
Medical problems
Gastrointestinal Hormones
Bioactivity
Obesity
cholecystokinin 8
Degradation
Peptides
Therapeutics

Cite this

@article{33e41943e75d4c95a77109fbed262359,
title = "(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes",
abstract = "BACKGROUND: Cholecystokinin (CCK) is a gastrointestinal hormone that has been proposed as a potential therapeutic option for obesity-diabetes. As such, (pGlu-Gln)-CCK-8 is an N-terminally modified CCK-8 analogue with improved biological effectiveness over the native peptide.METHODS: The current study has examined the in vitro stability, biological activity and in vivo therapeutic applicability of a novel second generation mini-PEGylated form of (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG].RESULTS: (pGlu-Gln)-CCK-8[mPEG] was completely resistant to enzymatic degradation and in addition displayed similar insulinotropic (p",
author = "Nigel Irwin and P Frizelle and Finbarr O'Harte and Peter Flatt",
year = "2013",
month = "4",
day = "10",
doi = "10.1016/j.bbagen.2013.04.004",
language = "English",
volume = "1830",
pages = "4009--4016",
journal = "BBA - General Subjects",
issn = "0304-4165",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - (pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes

AU - Irwin, Nigel

AU - Frizelle, P

AU - O'Harte, Finbarr

AU - Flatt, Peter

PY - 2013/4/10

Y1 - 2013/4/10

N2 - BACKGROUND: Cholecystokinin (CCK) is a gastrointestinal hormone that has been proposed as a potential therapeutic option for obesity-diabetes. As such, (pGlu-Gln)-CCK-8 is an N-terminally modified CCK-8 analogue with improved biological effectiveness over the native peptide.METHODS: The current study has examined the in vitro stability, biological activity and in vivo therapeutic applicability of a novel second generation mini-PEGylated form of (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG].RESULTS: (pGlu-Gln)-CCK-8[mPEG] was completely resistant to enzymatic degradation and in addition displayed similar insulinotropic (p

AB - BACKGROUND: Cholecystokinin (CCK) is a gastrointestinal hormone that has been proposed as a potential therapeutic option for obesity-diabetes. As such, (pGlu-Gln)-CCK-8 is an N-terminally modified CCK-8 analogue with improved biological effectiveness over the native peptide.METHODS: The current study has examined the in vitro stability, biological activity and in vivo therapeutic applicability of a novel second generation mini-PEGylated form of (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG].RESULTS: (pGlu-Gln)-CCK-8[mPEG] was completely resistant to enzymatic degradation and in addition displayed similar insulinotropic (p

U2 - 10.1016/j.bbagen.2013.04.004

DO - 10.1016/j.bbagen.2013.04.004

M3 - Article

VL - 1830

SP - 4009

EP - 4016

JO - BBA - General Subjects

T2 - BBA - General Subjects

JF - BBA - General Subjects

SN - 0304-4165

IS - 8

ER -